Women ages 18 and above with platinum sensitive, recurrent ovarian, fallopian tube, or primary peritoneal cancer neede for research study.
A PHASE III RANDOMIZED CONTROLLED CLINICAL TRIAL OF CARBOPLATIN AND PACLITAXEL (OR GEMCITABINE) ALONE OR IN COMBINATION WITH BEVACIZUMAB (NSC #704865, IND #113912) FOLLOWED BY BEVACIZUMAB AND SECONDARY CYTOREDUCTIVE SURGERY IN PLATINUM-SENSITIVE, RECURRENT OVARIAN, PERITONEAL PRIMARY AND FALLOPIAN TUBE CANCER.
Obstetrics & Gynecology
Modesitt Susan, C
UVa Health System, the Department of Obstetrics and Gynecology, the division of Gynecologic Oncology, seeks Women ages 18 and above with platinum sensitive, recurrent ovarian, fallopian tube, or primary peritoneal cancer for research study. The purpose of the study is to compare the old treatment with the old treatment plus experimental drug, bevacizumab. Patients that are candidates for surgery will be randomly selected for surgery or to not have surgery before chemotherapy begins. Study involves taking an experimental medicine along with standard chemotherapy, blood draws, CT scans, urine tests and an EKG. Eligible patients will come to clinic for treatment for 6-8 visits every 3 weeks, each visit lasting 6-8 hours. No compensation is provided for this study. Contact Information: For more information please contact: Heather Lothamer, MSN 434-924-2745 or HLL5y@virginia.edu IRB-HSR #13501 Principal Investigator: Susan Modesitt, MD